scholarly journals High-flow oxygen for children’sairway surgery: randomised controlledtrial protocol (HAMSTER)

BMJ Open ◽  
2019 ◽  
Vol 9 (10) ◽  
pp. e031873
Author(s):  
Susan Humphreys ◽  
Britta Sylvia von Ungern-Sternberg ◽  
Justin Skowno ◽  
Tara Williams ◽  
Julia Taylor ◽  
...  

IntroductionHypoxaemia during anaesthesia for tubeless upper airway surgery in children with abnormal airways is common due to the complexity of balancing adequate depth of anaesthesia with maintenance of spontaneous breathing and providing an uninterrupted field of view of the upper airway for the surgeon. High-flow nasal oxygenation (HIGH-FLOW) can prolong safe apnoea time and be used in children with abnormal airways but to date has not been compared with the alternative technique of low-flow nasal oxygenation (LOW-FLOW). The aim is to investigate if use of HIGH-FLOW can reduce the number of hypoxaemic events requiring rescue oxygenation compared with LOW-FLOW.Methods and analysisHigh-flow oxygen for children’sairway surgery: randomised controlledtrial (HAMSTER) is a multicentre, unmasked, randomised controlled, parallel group, superiority trial comparing two oxygenation techniques during anaesthesia. Children (n=530) aged >37 weeks to 16 years presenting for elective tubeless upper airway surgery who fulfil inclusion but not exclusion criteria will be randomised prior to surgery to HIGH-FLOW or LOW-FLOW post induction of anaesthesia. Maintenance of anaesthesia with HIGH-FLOW requires Total IntraVenous Anaesthesia (TIVA) and with LOW-FLOW, either inhalational or TIVA at discretion of anaesthetist. The primary outcome is the incidence of hypoxaemic events requiring interruption of procedure for rescue oxygenation by positive pressure ventilation and the secondary outcome includes total hypoxaemia time, adverse cardiorespiratory events and unexpected paediatric intensive care admission admission. Hypoxaemia is defined as Sp02<90%. Analysis will be conducted on an intention-to-treat basis.Ethics and disseminationEthical approval has been obtained by Children’s Health Queensland Human Research Ethics Committee (HREC/18/QRCH/130). The trial commenced recruitment in 2018. The primary manuscript will be submitted for publication in a peer-reviewed journal.Trial registration numberThe HAMSTER is registered with the Australia and New Zealand Clinical TrialsRegistry: ACTRN12618000949280.

2021 ◽  
Author(s):  
Mathias Johansen ◽  
Sam J. Daniel ◽  
Thomas Engelhardt

2003 ◽  
Vol 50 (9) ◽  
pp. 967-967 ◽  
Author(s):  
Stuart Dolling ◽  
Nicola R. K. Anders ◽  
Sian E. Rolfe

2017 ◽  
Vol 40 ◽  
pp. e236
Author(s):  
H. Hosseiny ◽  
N. Naeimabadi ◽  
A. Najafi ◽  
R. Heidari ◽  
K. Sadeghniiat-Haghighi

2021 ◽  
Author(s):  
Guillaume Béraud ◽  
Jean-François Timsit ◽  
Henri Leleu

AbstractRemdesivir and dexamethasone are the only drugs providing reductions in the lengths of hospital stays for COVID-19 patients. We assessed the impacts of remdesivir on hospital-bed resources and budgets affected by the COVID-19 outbreak. A stochastic agent-based model was combined with epidemiological data available on the COVID-19 outbreak in France and data from two randomized control trials. Strategies involving treating with remdesivir only patients with low-flow oxygen and patients with low-flow and high-flow oxygen were examined. Treating all eligible low-flow oxygen patients during the entirety of the second wave would have decreased hospital-bed occupancy in conventional wards by 4% [2%; 7%] and intensive care unit (ICU)-bed occupancy by 9% [6%; 13%]. Extending remdesivir use to high-flow-oxygen patients would have amplified reductions in ICU-bed occupancy by up to 14% [18%; 11%]. A minimum remdesivir uptake of 20% was required to observe decreases in bed occupancy. Dexamethasone had effects of similar amplitude. Depending on the treatment strategy, using remdesivir would, in most cases, generate savings (up to 722€) or at least be cost neutral (an extra cost of 34€). Treating eligible patients could significantly limit the saturation of hospital capacities, particularly in ICUs. The generated savings would exceed the costs of medications.


Author(s):  
Robin T. Wu ◽  
Karl C. Bruckman ◽  
Kasey Li

Sign in / Sign up

Export Citation Format

Share Document